Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 844 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Attention Deficit and Disruptive Behavior Disorders Clear all
Terminated Early Phase 1 Interventional Results available

Amiloride Hydrochloride as an Effective Treatment for ADHD

NCT01733680
View directory record Official record
Conditions
ADHD
Interventions
amiloride, Behavioral
Drug · Behavioral
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 7, 2026, 4:13 AM EDT
Completed No phase listed Observational

Comparison of Self and Clinician Administered Rating Scales in Patients With ADHD

NCT00711724
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
13 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2010 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Food Additives Effects on EEG Profiles in College Students With ADHD

NCT03342469
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Artificial Food Coloring, Placebo
Other
Lead sponsor
American University
Other
Eligibility
18 Years to 24 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

Treating Parents With ADHD and Their Young Children Via Telehealth: A Hybrid Type I Effectiveness-Implementation Trial

NCT04240756
View directory record Official record
Conditions
ADHD, Parenting
Interventions
Behavioral Parent Training, Extended release mixed amphetamine salts (MAS)
Behavioral · Drug
Lead sponsor
University of Maryland, College Park
Other
Eligibility
3 Years to 65 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 7, 2026, 4:13 AM EDT
Terminated Not applicable Interventional

Pharmacogenomics for Improving Pediatric ADHD Treatment

NCT03730870
View directory record Official record
Conditions
Attention Deficit Disorders With Hyperactivity
Interventions
Pharmacogenomics report
Diagnostic Test
Lead sponsor
Clinical and Translational Genome Research Institute, Inc.
Other
Eligibility
6 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Hamilton, New Jersey • Mountainside, New Jersey • Toms River, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder

NCT02402166
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SPD489
Drug
Lead sponsor
Shire
Industry
Eligibility
4 Years to 5 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Newport Beach, California • Baltimore, Maryland • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 7, 2026, 4:13 AM EDT
Terminated Phase 3 Interventional

Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD

NCT06431256
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride capsules, Placebo HLD200 capsules
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
4 Years to 5 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Dothan, Alabama • Anaheim, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 4 Interventional Results available

Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta

NCT00181714
View directory record Official record
Conditions
ADHD
Interventions
methylphenidate HCl (Concerta)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 17 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Not applicable Interventional

Modified Comprehensive Behavioral Intervention for Tics (M_CBIT)

NCT02900144
View directory record Official record
Conditions
Tourette Syndrome, ADHD
Interventions
Modified Comprehensive Behavioral Intervention for Tics, Comprehensive Behavioral Intervention for Tics
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Early Prevention of Conduct Problems

NCT00051714
View directory record Official record
Conditions
Conduct Disorder
Interventions
Family-Based Preventive Intervention
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
33 Months to 63 Months
Enrollment
1,050 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 7, 2026, 4:13 AM EDT
Not yet recruiting Phase 4 Interventional

Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder

NCT07838311
View directory record Official record
Conditions
ADHD, Cannabis Use Disorder
Interventions
Delayed-release, extended-release methylphenidate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 26 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 7, 2026, 4:13 AM EDT
Terminated Phase 3 Interventional Results available

Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits

NCT01000064
View directory record Official record
Conditions
Traumatic Brain Injury, Attention Deficit Disorder
Interventions
Vyvanse, fMRI, Placebo
Drug · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
16 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 7, 2026, 4:13 AM EDT
Terminated Not applicable Interventional Results available

Galvanic Vestibular Stimulation and Motor Training in Traumatic Brain Injury Survivors

NCT01749800
View directory record Official record
Conditions
TBI, Attention Deficits, Motor Impairments
Interventions
GVS, Sham GVS, Armeo Spring
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

NCT00776009
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 4 Interventional

The Effect of a Once Daily Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents

NCT00566371
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Insomnia
Interventions
atomoxetine, placebo
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 4 Interventional Results available

Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia

NCT00607919
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Dyslexia
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 16 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
16
States / cities
Irvine, California • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 7, 2026, 4:13 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Near Infrared Spectroscopy in Children With Autism and ADHD

NCT01730079
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Autism, Autism Spectrum Disorders
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
4 Years to 8 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 7, 2026, 4:13 AM EDT
Not listed Not applicable Interventional

A Text Messaging (SMS) Intervention to Improve Adherence to Stimulant Medication in Adults With ADHD in the Primary Care Setting

NCT04189575
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
SMS Intervention
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 7, 2026, 4:13 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder

NCT00965419
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Edivoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 18 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
16
States / cities
Spring Valley, California • Gainesville, Florida • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 7, 2026, 4:13 AM EDT
Enrolling by invitation Phase 1 Interventional

Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities

NCT05301361
View directory record Official record
Conditions
Intellectual Disability, Fragile X Syndrome, Down Syndrome, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Oral Solution
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
6 Years to 24 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Sacramento, California • Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Not applicable Interventional Results available

Psychosocial Treatment for Attention Deficit Hyperactivity Disorder in Adults

NCT00278473
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Meta-Cognitive Therapy, Supportive Therapy
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00409708
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy, Behavior Therapy
Drug · Behavioral
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2011 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neuromodulation of Executive Function in the ADHD Brain

NCT04175028
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 66 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 7, 2026, 4:13 AM EDT